aibioAlzamend Neuro issues 361,743 shares on conversion of Series B preferred stock
Tickers ALZN
The shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.
Key facts
- Company
- Alzamend Neuro, Inc. (NASDAQ: ALZN)
- News type
- Financings
- Primary source
- Alzamend Neuro, Inc. 8-K (2025-10-09)
Alzamend Neuro, Inc. (Nasdaq: ALZN) issued an aggregate of 361,743 shares of common stock between October 1, 2025 and October 8, 2025, according to an 8-K filed October 9, 2025.
The shares were issued on conversion of approximately 839.2 shares of Series B Convertible Preferred Stock. Convertible preferred stock is a class of shares that holders can exchange for common stock under set terms. Each conversion adds common shares and spreads ownership across a larger share count.
The company said the shares were issued without SEC registration, relying on the exemption in Section 4(a)(2) of the Securities Act.
As of October 8, 2025, the Atlanta, Georgia company had 3,801,604 shares of common stock outstanding. Its common stock trades on The Nasdaq Capital Market.